SIEGEL R L , MILLER K D , GODING SAUER A , et al . Colorectal cancer statistics, 2020 [J ] . CA A Cancer J Clin , 2020 , 70 ( 3 ): 145 - 164 . DOI: 10.3322/caac.21601 http://doi.org/10.3322/caac.21601 https://onlinelibrary.wiley.com/doi/abs/10.3322/caac.21601 https://onlinelibrary.wiley.com/doi/abs/10.3322/caac.21601

CORTAZAR P , ZHANG L J , UNTCH M , et al . Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J ] . Lancet , 2014 , 384 ( 9938 ): 164 - 172 . DOI: 10.1016/S0140-6736(13)62422-8 http://doi.org/10.1016/S0140-6736(13)62422-8 https://linkinghub.elsevier.com/retrieve/pii/S0140673613624228 https://linkinghub.elsevier.com/retrieve/pii/S0140673613624228

BERRY D A , CIRRINCIONE C , HENDERSON I C , et al . Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer [J ] . JAMA , 2006 , 295 ( 14 ): 1658 - 1667 . DOI: 10.1001/jama.295.14.1658 http://doi.org/10.1001/jama.295.14.1658 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.295.14.1658 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.295.14.1658

GIANNI L , PIENKOWSKI T , IM Y H , et al . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial [J ] . Lancet Oncol , 2012 , 13 ( 1 ): 25 - 32 . DOI: 10.1016/S1470-2045(11)70336-9 http://doi.org/10.1016/S1470-2045(11)70336-9 https://linkinghub.elsevier.com/retrieve/pii/S1470204511703369 https://linkinghub.elsevier.com/retrieve/pii/S1470204511703369

SCHNEEWEISS A , CHIA S , HICKISH T , et al . Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase Ⅱ cardiac safety study (TRYPHAENA) [J ] . Ann Oncol , 2013 , 24 ( 9 ): 2278 - 2284 . DOI: 10.1093/annonc/mdt182 http://doi.org/10.1093/annonc/mdt182 https://linkinghub.elsevier.com/retrieve/pii/S0923753419369297 https://linkinghub.elsevier.com/retrieve/pii/S0923753419369297

SIKOV W M , BERRY D A , PEROU C M , et al . Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer: CALGB 40603 (Alliance) [J ] . J Clin Oncol , 2015 , 33 ( 1 ): 13 - 21 .

CARDOSO F , KYRIAKIDES S , OHNO S , et al . Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [J ] . Ann Oncol , 2019 , 30 ( 8 ): 1194 - 1220 . DOI: 10.1093/annonc/mdz173 http://doi.org/10.1093/annonc/mdz173 https://linkinghub.elsevier.com/retrieve/pii/S0923753419312876 https://linkinghub.elsevier.com/retrieve/pii/S0923753419312876

GRADISHAR W J , ANDERSON B O , ABRAHAM J , et al . Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology [J ] . J Natl Compr Cancer Netw , 2020 , 18 ( 4 ): 452 - 478 .

BURSTEIN H J , CURIGLIANO G , THÜRLIMANN B , et al . Customizing local and systemic therapies for women with early breast cancer: the St. Gallen international consensus guidelines for treatment of early breast cancer 2021 [J ] . Ann Oncol , 2021 , 32 ( 10 ): 1216 - 1235 . DOI: 10.1016/j.annonc.2021.06.023 http://doi.org/10.1016/j.annonc.2021.06.023 https://linkinghub.elsevier.com/retrieve/pii/S0923753421021049 https://linkinghub.elsevier.com/retrieve/pii/S0923753421021049

DOWSETT M , ELLIS M J , DIXON J M , et al . Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic [J ] . NPJ Breast Cancer , 2020 , 6 : 21 . DOI: 10.1038/s41523-020-0168-9 http://doi.org/10.1038/s41523-020-0168-9 https://doi.org/10.1038/s41523-020-0168-9 https://doi.org/10.1038/s41523-020-0168-9

NABHOLTZ J M , BUZDAR A , POLLAK M , et al . Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group [J ] . J Clin Oncol , 2000 , 18 ( 22 ): 3758 - 3767 . DOI: 10.1200/JCO.2000.18.22.3758 http://doi.org/10.1200/JCO.2000.18.22.3758 https://ascopubs.org/doi/10.1200/JCO.2000.18.22.3758 https://ascopubs.org/doi/10.1200/JCO.2000.18.22.3758

SMITH I E , DOWSETT M , EBBS S R , et al . Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial [J ] . J Clin Oncol , 2005 , 23 ( 22 ): 5108 - 5116 . DOI: 10.1200/JCO.2005.04.005 http://doi.org/10.1200/JCO.2005.04.005 https://ascopubs.org/doi/10.1200/JCO.2005.04.005 https://ascopubs.org/doi/10.1200/JCO.2005.04.005

CATALIOTTI L , BUZDAR A U , NOGUCHI S , et al . Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial [J ] . Cancer , 2006 , 106 ( 10 ): 2095 - 2103 . DOI: 10.1002/cncr.21872 http://doi.org/10.1002/cncr.21872 https://onlinelibrary.wiley.com/doi/10.1002/cncr.21872 https://onlinelibrary.wiley.com/doi/10.1002/cncr.21872

MASUDA N , SAGARA Y , KINOSHITA T , et al . Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial [J ] . Lancet Oncol , 2012 , 13 ( 4 ): 345 - 352 . DOI: 10.1016/S1470-2045(11)70373-4 http://doi.org/10.1016/S1470-2045(11)70373-4 https://linkinghub.elsevier.com/retrieve/pii/S1470204511703734 https://linkinghub.elsevier.com/retrieve/pii/S1470204511703734

EIERMANN W , PAEPKE S , APPFELSTAEDT J , et al . Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study [J ] . Ann Oncol , 2001 , 12 ( 11 ): 1527 - 1532 . DOI: 10.1023/A:1013128213451 http://doi.org/10.1023/A:1013128213451 https://linkinghub.elsevier.com/retrieve/pii/S0923753419543794 https://linkinghub.elsevier.com/retrieve/pii/S0923753419543794

SEMIGLAZOV V , KLETSEL A , SEMIGLAZOV V , et al . Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0) [J ] . J Clin Oncol , 2005 , 23 (16_suppl): 530 . DOI: 10.1200/jco.2005.23.16_suppl.530 http://doi.org/10.1200/jco.2005.23.16_suppl.530 http://ascopubs.org/doi/10.1200/jco.2005.23.16_suppl.530 http://ascopubs.org/doi/10.1200/jco.2005.23.16_suppl.530

ELLIS M J , SUMAN V J , HOOG J , et al . Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype: ACOSOG Z1031 [J ] . J Clin Oncol , 2011 , 29 ( 17 ): 2342 - 2349 . DOI: 10.1200/JCO.2010.31.6950 http://doi.org/10.1200/JCO.2010.31.6950 https://ascopubs.org/doi/10.1200/JCO.2010.31.6950 https://ascopubs.org/doi/10.1200/JCO.2010.31.6950

QUENEL-TUEUX N , DEBLED M , RUDEWICZ J , et al . Clinical and genomic analysis of a randomised phase Ⅱ study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer [J ] . Br J Cancer , 2015 , 113 ( 4 ): 585 - 594 . DOI: 10.1038/bjc.2015.247 http://doi.org/10.1038/bjc.2015.247 https://doi.org/10.1038/bjc.2015.247 https://doi.org/10.1038/bjc.2015.247

LEREBOURS F , RIVERA S , MOURET-REYNIER M A , et al . Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: results of the UNICANCER CARMINA 02 French trial (UCBG 0609) [J ] . Cancer , 2016 , 122 ( 19 ): 3032 - 3040 . DOI: 10.1002/cncr.30143 http://doi.org/10.1002/cncr.30143 https://onlinelibrary.wiley.com/doi/10.1002/cncr.30143 https://onlinelibrary.wiley.com/doi/10.1002/cncr.30143

MA C X , SUMAN V , LEITCH A M , et al . Abstract GS4-05: neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage Ⅱ or Ⅲ estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (alliance A011106) [C ] . American Association for Cancer Research , 2021 .

ALLEVI G , STRINA C , ANDREIS D , et al . Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer [J ] . Br J Cancer , 2013 , 108 ( 8 ): 1587 - 1592 . DOI: 10.1038/bjc.2013.151 http://doi.org/10.1038/bjc.2013.151 https://doi.org/10.1038/bjc.2013.151 https://doi.org/10.1038/bjc.2013.151

CARPENTER R , DOUGHTY J C , CORDINER C , et al . Optimum duration of neoadjuvant letrozole to permit breast conserving surgery [J ] . Breast Cancer Res Treat , 2014 , 144 ( 3 ): 569 - 576 . DOI: 10.1007/s10549-014-2835-8 http://doi.org/10.1007/s10549-014-2835-8 http://link.springer.com/10.1007/s10549-014-2835-8 http://link.springer.com/10.1007/s10549-014-2835-8

FONTEIN D B , CHAREHBILI A , NORTIER J W , et al . Efficacy of six months neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients: a phase Ⅱ trial [J ] . Eur J Cancer , 2014 , 50 ( 13 ): 2190 - 2200 . DOI: 10.1016/j.ejca.2014.05.010 http://doi.org/10.1016/j.ejca.2014.05.010 https://linkinghub.elsevier.com/retrieve/pii/S0959804914006601 https://linkinghub.elsevier.com/retrieve/pii/S0959804914006601

DIXON J M , RENSHAW L , MACASKILL E J , et al . Increase in response rate by prolonged treatment with neoadjuvant letrozole [J ] . Breast Cancer Res Treat , 2009 , 113 ( 1 ): 145 - 151 . DOI: 10.1007/s10549-008-9915-6 http://doi.org/10.1007/s10549-008-9915-6 http://link.springer.com/10.1007/s10549-008-9915-6 http://link.springer.com/10.1007/s10549-008-9915-6

SEMIGLAZOV V F , SEMIGLAZOV V V , DASHYAN G A , et al . Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer [J ] . Cancer , 2007 , 110 ( 2 ): 244 - 254 . DOI: 10.1002/cncr.22789 http://doi.org/10.1002/cncr.22789 https://onlinelibrary.wiley.com/doi/10.1002/cncr.22789 https://onlinelibrary.wiley.com/doi/10.1002/cncr.22789

ALBA E , CALVO L , ALBANELL J , et al . Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-Ⅱ study [J ] . Ann Oncol , 2012 , 23 ( 12 ): 3069 - 3074 . DOI: 10.1093/annonc/mds132 http://doi.org/10.1093/annonc/mds132 https://linkinghub.elsevier.com/retrieve/pii/S0923753419374708 https://linkinghub.elsevier.com/retrieve/pii/S0923753419374708

SPRING L M , GUPTA A , REYNOLDS K L , et al . Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis [J ] . JAMA Oncol , 2016 , 2 ( 11 ): 1477 - 1486 . DOI: 10.1001/jamaoncol.2016.1897 http://doi.org/10.1001/jamaoncol.2016.1897 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.1897 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.1897

WANG Y L , HE L , SONG Y H , et al . The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis [J ] . BMC Womens Health , 2020 , 20 ( 1 ): 17 . DOI: 10.1186/s12905-020-0879-y http://doi.org/10.1186/s12905-020-0879-y https://doi.org/10.1186/s12905-020-0879-y https://doi.org/10.1186/s12905-020-0879-y

GRADISHAR W J , MORAN M S , ABRAHAM J , et al . NCCN guidelines ® insights: breast cancer, version 4.2021 [J ] . J Natl Compr Canc Netw , 2021 , 19 ( 5 ): 484 - 493 . DOI: 10.6004/jnccn.2021.0023 http://doi.org/10.6004/jnccn.2021.0023 https://jnccn.org/view/journals/jnccn/19/5/article-p484.xml https://jnccn.org/view/journals/jnccn/19/5/article-p484.xml

SATO N , MASUDA N , MORIMOTO T , et al . Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks’ exemestane exposure in patients with estrogen receptor-positive breast cancer: a multicenter, open-label, phase Ⅱ study [J ] . Cancer Med , 2019 , 8 ( 12 ): 5468 - 5481 . DOI: 10.1002/cam4.2423 http://doi.org/10.1002/cam4.2423 https://onlinelibrary.wiley.com/doi/10.1002/cam4.2423 https://onlinelibrary.wiley.com/doi/10.1002/cam4.2423

MATSUNUMA R , WATANABE T , HOZUMI Y , et al . Preoperative concurrent endocrine therapy with chemotherapy in luminal B-like breast cancer [J ] . Breast Cancer , 2020 , 27 ( 5 ): 819 - 827 . DOI: 10.1007/s12282-020-01077-0 http://doi.org/10.1007/s12282-020-01077-0 https://doi.org/10.1007/s12282-020-01077-0 https://doi.org/10.1007/s12282-020-01077-0

SPRING L M , WANDER S A , ANDRE F , et al . Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future [J ] . Lancet , 2020 , 395 ( 10226 ): 817 - 827 . DOI: 10.1016/S0140-6736(20)30165-3 http://doi.org/10.1016/S0140-6736(20)30165-3 https://linkinghub.elsevier.com/retrieve/pii/S0140673620301653 https://linkinghub.elsevier.com/retrieve/pii/S0140673620301653

MA C X , GAO F , LUO J Q , et al . NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer [J ] . Clin Cancer Res , 2017 , 23 ( 15 ): 4055 - 4065 . DOI: 10.1158/1078-0432.CCR-16-3206 http://doi.org/10.1158/1078-0432.CCR-16-3206 https://aacrjournals.org/clincancerres/article/23/15/4055/256945/NeoPalAna-Neoadjuvant-Palbociclib-a-Cyclin https://aacrjournals.org/clincancerres/article/23/15/4055/256945/NeoPalAna-Neoadjuvant-Palbociclib-a-Cyclin

HURVITZ S A , MARTIN M , PRESS M F , et al . Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase Ⅱ neoadjuvant study in HR+/HER2- breast cancer [J ] . Clin Cancer Res , 2020 , 26 ( 3 ): 566 - 580 . DOI: 10.1158/1078-0432.CCR-19-1425 http://doi.org/10.1158/1078-0432.CCR-19-1425 https://aacrjournals.org/clincancerres/article/26/3/566/83167/Potent-Cell-Cycle-Inhibition-and-Upregulation-of https://aacrjournals.org/clincancerres/article/26/3/566/83167/Potent-Cell-Cycle-Inhibition-and-Upregulation-of

COTTU P , D’HONDT V , DUREAU S , et al . Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer [J ] . Ann Oncol , 2018 , 29 ( 12 ): 2334 - 2340 . DOI: 10.1093/annonc/mdy448 http://doi.org/10.1093/annonc/mdy448 https://linkinghub.elsevier.com/retrieve/pii/S0923753419342358 https://linkinghub.elsevier.com/retrieve/pii/S0923753419342358

JOHNSTON S , PUHALLA S , WHEATLEY D , et al . Randomized phase Ⅱ study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial [J ] . J Clin Oncol , 2019 , 37 ( 3 ): 178 - 189 .

MILLER T W , REXER B N , GARRETT J T , et al . Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer [J ] . Breast Cancer Res , 2011 , 13 ( 6 ): 224 . DOI: 10.1186/bcr3039 http://doi.org/10.1186/bcr3039 http://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3039 http://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3039

SAURA C , HLAUSCHEK D , OLIVEIRA M , et al . Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial [J ] . Lancet Oncol , 2019 , 20 ( 9 ): 1226 - 1238 . DOI: 10.1016/S1470-2045(19)30334-1 http://doi.org/10.1016/S1470-2045(19)30334-1 https://linkinghub.elsevier.com/retrieve/pii/S1470204519303341 https://linkinghub.elsevier.com/retrieve/pii/S1470204519303341

BASELGA J , SEMIGLAZOV V , VAN DAM P , et al . Phase Ⅱ randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer [J ] . J Clin Oncol , 2009 , 27 ( 16 ): 2630 - 2637 . DOI: 10.1200/JCO.2008.18.8391 http://doi.org/10.1200/JCO.2008.18.8391 https://ascopubs.org/doi/10.1200/JCO.2008.18.8391 https://ascopubs.org/doi/10.1200/JCO.2008.18.8391

ARNEDOS M , ROULLEAUX DUGAGE M , PEREZ-GARCIA J , et al . Window of opportunity trials for biomarker discovery in breast cancer [J ] . Curr Opin Oncol , 2019 , 31 ( 6 ): 486 - 492 . DOI: 10.1097/CCO.0000000000000583 http://doi.org/10.1097/CCO.0000000000000583 https://journals.lww.com/10.1097/CCO.0000000000000583 https://journals.lww.com/10.1097/CCO.0000000000000583

SERRANO D , LAZZERONI M , GANDINI S , et al . A randomized phase Ⅱ presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer [J ] . Breast Cancer Res , 2013 , 15 ( 3 ): R47 . DOI: 10.1186/bcr3439 http://doi.org/10.1186/bcr3439 http://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3439 http://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3439

COHEN A L , FACTOR R E , MOONEY K , et al . POWERPIINC (preoperative window of endocrine therapy provides information to increase compliance) trial: changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen [J ] . Breast , 2017 , 31 : 219 - 223 . DOI: 10.1016/j.breast.2016.11.016 http://doi.org/10.1016/j.breast.2016.11.016 https://linkinghub.elsevier.com/retrieve/pii/S0960977616302508 https://linkinghub.elsevier.com/retrieve/pii/S0960977616302508

CROSHAW R , SHAPIRO-WRIGHT H , SVENSSON E , et al . Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients [J ] . Ann Surg Oncol , 2011 , 18 ( 11 ): 3160 - 3163 . DOI: 10.1245/s10434-011-1919-5 http://doi.org/10.1245/s10434-011-1919-5 http://link.springer.com/10.1245/s10434-011-1919-5 http://link.springer.com/10.1245/s10434-011-1919-5

SYMMANS W F , PEINTINGER F , HATZIS C , et al . Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy [J ] . J Clin Oncol , 2007 , 25 ( 28 ): 4414 - 4422 . DOI: 10.1200/JCO.2007.10.6823 http://doi.org/10.1200/JCO.2007.10.6823 https://ascopubs.org/doi/10.1200/JCO.2007.10.6823 https://ascopubs.org/doi/10.1200/JCO.2007.10.6823

NIELSEN T O , LEUNG S C Y , RIMM D L , et al . Assessment of Ki-67 in breast cancer: updated recommendations from the international Ki-67 in breast cancer working group [J ] . J Natl Cancer Inst , 2020 , 113 ( 7 ): 808 - 819 . DOI: 10.1093/jnci/djaa201 http://doi.org/10.1093/jnci/djaa201 https://academic.oup.com/jnci/article/113/7/808/6053794 https://academic.oup.com/jnci/article/113/7/808/6053794

ELLIS M J , TAO Y , LUO J Q , et al . Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics [J ] . J Natl Cancer Inst , 2008 , 100 ( 19 ): 1380 - 1388 . DOI: 10.1093/jnci/djn309 http://doi.org/10.1093/jnci/djn309 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djn309 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djn309

STAFFORD A , WILLIAMS A , EDMISTON K , et al . Axillary response in patients undergoing neoadjuvant endocrine treatment for node-positive breast cancer: systematic literature review and NCDB analysis [J ] . Ann Surg Oncol , 2020 , 27 ( 12 ): 4669 - 4677 . DOI: 10.1245/s10434-020-08905-9 http://doi.org/10.1245/s10434-020-08905-9 https://doi.org/10.1245/s10434-020-08905-9 https://doi.org/10.1245/s10434-020-08905-9

WEISS A , WONG S , GOLSHAN M , et al . Patterns of axillary management in stages 2 and 3 hormone receptor-positive breast cancer by initial treatment approach [J ] . Ann Surg Oncol , 2019 , 26 ( 13 ): 4326 - 4336 . DOI: 10.1245/s10434-019-07785-y http://doi.org/10.1245/s10434-019-07785-y https://doi.org/10.1245/s10434-019-07785-y https://doi.org/10.1245/s10434-019-07785-y

ELLIS M J , SUMAN V J , HOOG J , et al . Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American college of surgeons oncology group Z1031 trial (alliance) [J ] . J Clin Oncol , 2017 , 35 ( 10 ): 1061 - 1069 . DOI: 10.1200/JCO.2016.69.4406 http://doi.org/10.1200/JCO.2016.69.4406 https://ascopubs.org/doi/10.1200/JCO.2016.69.4406 https://ascopubs.org/doi/10.1200/JCO.2016.69.4406

KANTOR O , WONG S , WEISS A , et al . Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer [J ] . NPJ Breast Cancer , 2020 , 6 : 35 . DOI: 10.1038/s41523-020-00177-6 http://doi.org/10.1038/s41523-020-00177-6 https://doi.org/10.1038/s41523-020-00177-6 https://doi.org/10.1038/s41523-020-00177-6

SMITH I , ROBERTSON J , KILBURN L , et al . Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial [J ] . Lancet Oncol , 2020 , 21 ( 11 ): 1443 - 1454 . DOI: 10.1016/S1470-2045(20)30458-7 http://doi.org/10.1016/S1470-2045(20)30458-7 https://linkinghub.elsevier.com/retrieve/pii/S1470204520304587 https://linkinghub.elsevier.com/retrieve/pii/S1470204520304587

HARBECK N , GLUZ O , KUEMMEL S , et al . Abstract GS4-04: endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), recurrence score <26 and Ki-67 response after preoperative endocrine therapy: primary outcome results from the WSG-ADAPT HR+/HER2- trial [C ] . American Association for Cancer Research , 2021 .